Date
28 September 2023
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Investment platform Benzinga writes on the launch of the first report from the Foundation's Generic & Biosimilar Medicines Programme. The report profiles five major generic drug companies, Cipla, Hikma, Sun Pharma, Teva and Viatris, assessing them on their efforts to expand access to their products in low- and middle-income countries (LMICs).
Direct links
The article notes that while the report captures examples of postive initiatives from the companies in scope, it also shows that there are far too many patients in LMICs who do not have access to the treatments they need.
Examples in the article include the fact that out of 50 products assessed within the scope of the report, only one has an associated pricing strategy that takes patient ability to pay into account.
Read the Foundation's report on generic and biosimilar medicine manufacturers.